Trials / Terminated
TerminatedNCT05878704
Study of GBT021601 in Participants With Renal Impairment
A Phase I, Open-Label, Single-Dose, Non-Randomized, Parallel Group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of GBT021601, an Oral Hemoglobin S Polymerization Inhibitor, in Adult Participants With Renal Impairment
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Renal Impairment study of GBT021601.
Detailed description
This is a Phase 1, two-part, non-randomized, open-label, parallel group study to evaluate the PK, safety, and tolerability of GBT021601 following a single dose administration in adult participants with RI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GBT021601 | Oral |
Timeline
- Start date
- 2023-06-29
- Primary completion
- 2024-07-29
- Completion
- 2024-07-29
- First posted
- 2023-05-26
- Last updated
- 2024-10-15
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05878704. Inclusion in this directory is not an endorsement.